Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilengitide Maintenance in AML
NCT00089388Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2004
- Primary completion
- Jun 2006
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of cilengitide in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Jul 2004; status: terminated.
02
Drugs
cilengitide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00089388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089388.